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The feasibility and efficacy of up-front high-dose sequential
chemotherapy followed by autologous stem cell transplanta-
tion (ASCT) in previously untreated adults (median age 33
years; range 15–64) with Burkitt lymphoma (BL), Burkitt-like
lymphoma (BLL) or lymphoblastic lymphoma (LyLy), both
without central nervous system or extensive bone marrow
involvement was investigated in a multicenter phase II study.
Treatment consisted of two sequential high-dose chemother-
apy induction courses incorporating prednisone, cyclopho-
sphamide, doxorubicin, etoposide and mitoxantrone, without
high-dose methotrexate or high-dose cytarabine. Patients with
at least PR went on with BEAM and ASCT. Protocol treatment
was completed by 23/27 (85%) BL/BLL and 13/15 (87%) LyLy
patients. Median treatment duration until BEAM was 70 (range:
50–116) days. No toxic deaths occurred. Response to treatment
was complete response (CR) 81% and partial response (PR)
11% for BL/BLL, CR 73% and PR 20% for LyLy. At a median
follow-up of 61 months of patients still alive, six BL/BLL and
eight LyLy patients have died. The actuarial 5-year overall and
event-free survival estimates are 81 and 73% for BL/BLL vs 46
and 40% for LyLy patients. In conclusion, this short up-front
high-dose sequential chemotherapy regimen, followed by
ASCT is highly effective in adults with BL/BLL with limited
bone marrow involvement, but less so in patients with LyLy.
Leukemia (2005) 19, 945–952. doi:10.1038/sj.leu.2403733
Published online 31 March 2005
Keywords: adult Burkitt lymphoma; autologous stem cell
transplantation; lymphoblastic lymphoma; Burkitt-like lymphoma
Introduction
Sporadic Burkitt lymphoma (BL) is a rare and highly aggressive
B-cell tumor.1 Although it accounts for up to 40% of B-cell
lymphoma in childhood, less than 5% of the lymphomas in
adults are BL.
Age, central nervous system and/or bone marrow involve-
ment, high serum LDH and bulky tumor mass at diagnosis are
poor prognostic factors.2–4 Current treatment strategies devel-
oped for children mainly consist of a relatively short course of
intensive risk-adapted chemotherapy, incorporating (fractio-
nated) cyclophosphamide, doxorubicin, vincristine and steroids
in combination with high-dose intravenous methotrexate (MTX),
high-dose cytarabine (Ara-C), and sometimes also etoposide.3–7
With this type of approach, treatment outcome in children is
excellent, with over 80% cure rates even in patients with
adverse prognostic risk factors at diagnosis. As a result of the
relative rareness of BL in adults, only few data on treatment
outcome in these patients have been reported, with higher cure
rates in adult patients treated with a ‘pediatric’ type of therapy
approach.8–12 However, children had superior outcome and
tolerated treatment better than older patients.8
Lymphoblastic lymphoma (LyLy), a disease mainly seen in
adolescents has a very poor outcome in adults treated with
conventional chemotherapy. Adult patients with extensive bone
marrow involvement at presentation have better outcomes with
more intensive treatment approaches such as those used for
treatment of acute lymphoblastic leukemia,13–16 but the optimal
treatment for patients with less extensive disease remains to be
elucidated.
Based on promising results of autologous stem cell transplan-
tation (ASCT) in patients with aggressive lymphoma in first
remission, including nonleukemic BL, Burkitt-like lymphoma
(BLL) and LyLy,17–22 the Dutch–Belgian Hemato-Oncology
Cooperative Group (HOVON) initiated a multicenter phase II
study in December 1994 to evaluate a strategy of short intensive
sequential chemotherapy, and subsequent ASCT in adult
patients. We present the results of this treatment in patients
with BL/BLL and LyLy with a median follow-up of more than 5
years for patients still alive.
Methods
Patients
Between December 1994 and February 2003, patients with
newly diagnosed BL, BLL or LyLy in the Netherlands and
Belgium were enrolled in a multicenter phase II study HOVON-
27BL. Patients had to be fully staged, including CT scanning of
the thorax and abdomen, bone marrow aspiration and biopsy,
and cerebrospinal fluid examination. The following entry
criteria had to be fulfilled: age 18–65 years, Ann Arbor stage
II–IV, or I (E) in combination with either bulky (410 cm) tumor
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or with serum LDH41.5 times the upper normal limit of the
participating institution; WHO-performance score 0, 1, or 2, no
central nervous system (CNS) localization, and less than 30%
bone marrow infiltration. Patients were not eligible if they were
HIV-positive, or had severe concomitant disease, prior malig-
nancy or major organ dysfunction not directly related to
infiltration or obstruction by lymphoma. Except for treatment
with steroids in the week before starting protocol treatment, no
prior chemotherapy was allowed. Renal dysfunction due to
tumor obstruction or hyperuricosemia was accepted at entry,
but required correction before the start of treatment. In the
present analysis, patients were retrospectively classified to the
age-adjusted International Prognostic Index (aa-IPI), as well as a
low- or high-risk group according to the risk grading based on
Magrath et al9 and used by the United Kingdom Lymphoma
Group (UKLG) for BL23 and others.24 According to this grading
system, patients with all of the following features present: (i) Ann
Arbor stage I–II(E), (ii) tumor mass o10 cm, (iii) normal serum
LDH, and (iv) WHO performance 0 or 1 were graded as low
risk, all other patients as high risk. All patients gave informed
consent for study participation according to the regulations of
the Dutch health authorities. The study was performed and
evaluated by HOVON according to the Helsinki agreement.
Pathology
Biopsies were reviewed and classified both according to the
REAL25 and WHO1 classification schemes. Tissue blocks were
collected to perform additional fluorescent in situ hybridization
(FISH) analysis for the detection of MYC/8q24 breakpoints.26
Treatment
Initial treatment consisted of two consecutive high-dose
chemotherapy combinations. Induction-I consisted of
1000 mg/m2 cyclophosphamide i.v., 12 hourly on days 1 and
2 (total dose: 4000 mg/m2); 35 mg/m2 doxorubicin i.v., on days
1 and 2 (total dose 70 mg/m2); 100 mg prednisone for 5 days.
Uromithexan (Mesna) 200 mg/m2 was infused every 4 h, starting
10 min before the cyclophosphamide infusion; the final uro-
mithexan infusion was administered 8 h after the last cyclopho-
sphamide infusion. Induction-II consisted of 250 mg/m2
etoposide, every 12 h i.v. for 4 days (total dose 2000 mg/m2);
30 mg/m2 mitoxantrone i.v. on day 1; and 100 mg prednisone
for 5 days. Induction-II was given as soon as hematological
recovery, defined as a rising platelet and neutrophil count in
excess of 100 109/l and 1.0 109/l, respectively, was ob-
served after induction-I. After each induction course, patients
received 5 mg/kg G-CSF (Filgrastim) s.c. daily from day 5 until a
neutrophil count (ANC) was observed of at least 0.5 109/l for
two consecutive days.
Peripheral blood stem cells were harvested and cryo-
preserved preferably after induction-I or otherwise after induc-
tion-II according to standard institutional harvesting procedures,
provided the bone marrow did not contain lymphoma on
histology (anymore). No CD34 selection or purging was
performed. Patients attaining at least a partial response (PR)
after induction-II, and from whom a sufficient stem cell harvest
of at least 2.5 106 CD34þ cells/kg had been obtained, were
subsequently treated with high-dose therapy and ASCT. High-
dose chemotherapy consisted of BEAM: 300 mg/m2 carmustine
i.v. on day 6; 100 mg/m2 etoposide, infused in 1 h, every 12 h,
for a total of 4 days starting on day 5; 100 mg/m2 Ara-C,
infused in 1 h, every 12 h, for 4 days starting on day 5; 140 mg/
m2 melphalan i.v. on day 1. Stem cells were reinfused on day
0. Intrathecal MTX 15 mg was used as CNS prophylaxis and
administered at diagnosis, during induction-I, after recovery
from induction-I and -II, and before BEAM for a total of five
injections.
During treatment, all patients received hematological suppor-
tive care according to the rules and guidelines of the
participating institution. This included vigorous hydration,
allopurinol, platelet- and red blood cell transfusions, prophy-
lactic oral antibacterial and antifungal treatment, as well as
immediate treatment with i.v. broad-spectrum antibiotics and/or
i.v. antifungal treatment in case of fever and/or documented or
suspected infection. Patients with bulky disease at presentation
(X10 cm) could be treated with additional (involved field)
radiotherapy on PR sites after recovery from ASCT. This was left
to the discretion of the treatment center. No further maintenance
therapy was given.
Response to treatment and toxicity
Tumor response was assessed after induction-II, after ASCT, and
after additional radiotherapy (if given) according to staging
procedures described at diagnosis. Responses were classified as
complete response (CR), unconfirmed complete response, PR,
stable disease or progressive disease.27 All side effects except
hematological toxicity, nausea and hair loss were graded
according to the National Cancer Institute Common Toxicity
Criteria grading system. Infectious events were graded according
to the WHO grading system for infections. Hematological
recovery after each treatment course was assessed separately.
Statistical analysis
The data were analyzed as of July 2004. The study end points
were CR rate, response rate (CRþ PR), event-free survival (EFS),
progression-free survival (PFS) and overall survival (OS). All
survival end points were calculated from start of treatment on an
intention-to-treat basis. EFS was defined as the time to
progression, relapse or death from any cause, whichever came
first. Patients without progression or relapse, who were still
alive, were censored at the date of last contact. PFS was
calculated from start of induction-I until progression, relapse or
death from NHL; patients without progression or relapse who
were still alive at the date of last contact, or who died from
a non-NHL-related cause, were censored. OS was defined as the
time to death from any cause; patients still alive were censored
at the date of last contact.27 However, as none of the patients
died from a non-lymphoma-related cause, EFS and PFS were
equal, and therefore PFS will not be considered separately. The
Kaplan–Meier method was used to estimate OS and EFS and
95% confidence intervals (CI) were calculated. Kaplan–Meier
survival curves were generated to illustrate survival, and the log-
rank test was used to compare survival between subgroups. All
reported P-values are two-sided and a significance level of
a¼ 0.05 was used.
Results
From 12 centers 42 patients with an original diagnosis of BL or
BLL (n¼ 27), T-lymphoblastic lymphoma (T-LyLy) (n¼ 13) or
B-lymphoblastic lymphoma (B-LyLy) (n¼ 2) were included in
the study. All lymphoblastic cases were confirmed upon
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pathology review that included staining for terminal deoxy-
nucleotidyl transferase (TdT). At review, particular attention
was paid to the well-known difficulties in differentiating
between BL, BLL and diffuse large B-cell lymphoma (DLBCL)
according to the REAL classification25,28 as well as BL, atypical
BL (aBL) and DLBCL according to the WHO classification.1
Review included histology, immunophenotype (B-cell markers,
Ki-67/MIB1, CD10 and bcl2) as well as FISH for breakpoints
in MYC/8q24.26 A total of 27 cases with a diagnosis of BL or
BLL as defined by the REAL classification had been included.
All cases showed a classical starry sky pattern and a mono-
tonous proliferation of medium-sized blasts as well as
many mitotic figures with a Ki-67/MIB-1 proliferation index
of 490%. Morphological details varied to some extent, some
cases having slightly more variation in nuclear size and
the number of nucleoli (BLL). Moreover, all cases were of
mature B cell origin (CD20 positive and immunoglobulin
positive and/or TdT negative). Thus, also upon review, all cases
fulfilled the criteria of the REAL classification for BL or BLL.
However, in view of the current uncertainty on the histogenesis
of BLL, all cases were also reviewed according to the WHO
classification, which requires the presence of a MYC/8q24
breakpoint in all cases with atypical morphology to ascertain a
diagnosis of aBL; in consequence, all aBL cases lacking this
breakpoint should be classified as DLBCL. In 17 of 27 tumors,
FISH for MYC/8q24 breakpoint detection was successfully
performed. Of these 17 cases, 10 contained a MYC/8q24
breakpoint and seven were negative, the latter cases all being
reviewed as DLBCL according to the WHO classification. For
four cases with a classical histology and phenotype of BL in
which no FISH analysis could be performed, a diagnosis of BL
was maintained. Six cases with a morphology of aBL and/or
phenotype, without material necessary for FISH, were reviewed
as not evaluable.
Patient characteristics
The main clinical characteristics of both the BL and LyLy
patients are summarized in Table 1. The median age was
33 years, two patients with BL/BLL were older than 60 years.
Most patients presented with a good performance status. All
stage I(E) patients had both elevated serum LDH as well as bulky
disease. Stage IV disease and bone marrow involvement was
observed more frequently in patients with LyLy. Half of the
patients with BL/BLL and two-thirds of the patients with LyLy
presented with extranodal involvement. As expected, the
gastrointestinal tract was the most frequent site of extranodal
involvement in patients with BL/BLL (n¼ 7), but a variety of
other sites of involvement were observed as well (lung,
pericardial pleural in four, urogenital in three, bone marrow in
two, and liver, ascites, epidural, breast, paranasal sinus, adrenal
and soft tissue in one patient each). No apparent difference in
clinical presentation was detected between the different
morphological subgroups and between the breakpoint positive,
negative, and not tested cases of BL/BLL. All patients with LyLy
except one had a mediastinal mass at presentation. Lung,
pericardial, or pleural involvement was observed in 44%.
According to the aa-IPI, 37% of the BL/BLL and 53% of the
LyLy patients had high-intermediate or high risk. Serum LDH
levels were elevated in two-thirds of the patients, and in the
majority of those patients in excess of 1.5 times the upper
normal level. All but three patients had high-risk lymphoma
according to the UKLG risk score.
Treatment course
Treatment according to the protocol including ASCT was
completed by 23 (85%) BL/BLL and 13 (87%) LyLy patients.
No patient failed to mobilize adequate numbers of CD34-
positive cells for transplantation. Involved field radiotherapy
after ASCT was given to six BL/BLL and four LyLy patients.
Induction-II was given at a median of 27 days (range 16–51) and
BEAM followed by ASCT at a median of 70 days (range 50–116)
after the start of treatment. Six patients (four BL/BLL and two
LyLy) did not complete treatment because of progressive disease
(n¼ 3), less than partial response (n¼ 1), persistent bone
marrow involvement after induction-II (n¼ 1), or pulmonary
embolism (n¼ 1). Three of these patients ultimately reached CR
off protocol.
Toxicity
No toxic deaths occurred. The median time from start of
treatment to WBC recovery 41.0 109/l was 14 days (range
Table 1 Patient characteristics
BL/BLL LyLy
n (%) n (%)
Patients 27 (100) 15 (100)
Age median (years) 36 30
Range (15–64) (16–50)
Sex
Male 21 (78) 13 (87)
Female 6 (22) 2 (13)
Stage
I(E) 5 (19) 2 (13)
II 10 (37) 1 (7)
III 2 (7) 3 (20)
IV 10 (37) 9 (60)
B symptoms 13 (48) 6 (40)
Bulky (410 cm) tumor 12 (44) 9 (60)
Bone marrow involved 2 (7) 3 (20)
Extranodal involvement 13 (48) 10 (67)
X2 Extranodal sites 7 (26) 4 (27)
WHO performance score
0–1 23 (85) 14 (93)
41 4 (15) 1 (7)
LDH
pULN 9 (33) 5 (33)
1–1.5ULN 7 (26) 4 (27)
41.5ULN 11 (41) 6 (40)
Age-adjusted IPI
0–1 17 (63) 7 (47)
2–3 10 (37) 8 (53)
UKLG-index
Low risk 3 (11) 0 (0)
High risk 24 (89) 15 (100)
BL/BLL: Burkitt, Burkitt-like lymphoma; LyLy: lymphoblastic lympho-
ma; ULN: upper limit of normal; IPI: International prognostic index;
UKLG- index: United Kingdom Lymphoma Group risk index for Burkitt
lymphoma.23
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0–17) after induction-I, 15 days (range 5–29) after induction-II
and 13 days (range 8–30) after ASCT. The median time from start
of treatment to platelet recovery420 109/l was 13 days (range
0–26) after induction-I, 15 days (range 0–25) after induction-II
and 10 days (range 0–99) after ASCT. WHO grade 2–3 infections
were seen in 40% of patients during the aplastic phase after
induction-I, in 56% after induction-II and in 50% after ASCT. No
patient had WHO grade 4 infection. Severe mucositis, with CTC
grade 3–4 was observed in 39% of the patients after induction-II,
and in 39% after BEAM. This was the major nonhematological
toxicity (Table 2). No other grade 4 toxicity was observed.
Response and survival
Response to treatment is summarized in Table 3. The overall
response on protocol was 93% for both BL/BLL and LyLy.
Disease progression (including relapse) was observed during
treatment in one (4%) BL/BLL and two (14%) LyLy patients, and
after completion of treatment in seven (26%) BL/BLL and seven
(47%) LyLy patients. The primary site of progression was nodal
(three BL/BLL, three LyLy), extranodal (four BL/BLL, two LyLy),
or both (one BL/BLL, two LyLy). Specifically, meningeal disease
was observed thrice, in one BL/BLL patient and one LyLy patient
during induction-II, and after ASCT in one BL/BLL patient. No
relapses were observed in the six BL patients who underwent
radiotherapy. Two of the four patients with LyLy who underwent
local radiotherapy progressed after 6 and 20 months, both inside
(mediastinal) as well as outside the irradiation field. Three
patients with progression (two BL/BLL and one LyLy) are still
alive. With a median follow-up of 61 months of patients still
alive, 14 patients have died, all of lymphoma. No other fatal
events were observed. OS at 5 years is estimated to be 81% for
BL/BLL (95% CI 61–92) and 46% for LyLy (95% CI 20–68). EFS
at 5 years is 73% for BL/BLL (95% CI 51–86) and 40% for LyLy
(95% CI 16–63). Kaplan–Meier curves of OS and EFS are
depicted in Figure 1. No apparent differences were noted in the
probability of reaching a complete remission or progression of
disease for age, performance status, stage, number of extranodal
sites, LDH, aa-IPI, UKLG risk, the different morphological
subgroups or between the breakpoint positive, negative, and not
tested cases in BL/BLL. These subgroups were obviously too
small to draw any firm conclusion. Notably, despite the similar
initial response rate of patients with BL/BLL and LyLy, patients
with BL/BLL were far less likely to progress than patients with
LyLy.
Discussion
With a median follow-up of more than 5 years, this short
intensive therapy followed by BEAM and ASCT could cure 80%
of patients with BL/BLL without CNS or extensive bone marrow
involvement. However, results in patients with LyLy were less
favorable. Treatment of adult patients with ASCT according to
this protocol was feasible in a multicenter setting. Although
mucosal toxicity was extensive, no patient died of toxicity and
serious other toxicities were not observed. Treatment duration
was short, with a median time to last chemotherapy treatment of
only 2.3 months. As has been shown by others (Table 4), a short
duration of intensive therapy can be highly effective in BL/BLL.
The initial CR rate is high in most series with only few patients
progressing after 2 years.
When our results of up-front ASCT in adult BL/BLL are
compared to those of other treatment approaches reported in the
literature, several confounding issues must be addressed, in
addition to the fact that reports of treatment results on adults are
sparse. In general, the pathological diagnosis of BL in adult
patients is extremely difficult.28 Diagnostic difficulties mainly
concern some cases of DLBCL with BL features or BL with
somewhat variation in nuclear size and nucleolar distribution,
often called BLL in the REAL classification25 or aBL in the WHO
classification, the latter defined as a variant of BL with a proven
MYC/8q24 breakpoint.1 In previous clinical studies concerning
treatment outcome of BL, these variants have often been lumped
together, especially since ancillary techniques like FISH were
Table 3 Response and events
BL/BLL LyLy
n (%) n (%)
Patients 27 (100) 15 (100)
Response on protocol
Complete remission 22 (81) 11 (73)
Partial remission 3 (11) 3 (20)
Progression of disease 8 (30) 9 (60)
Progression before ASCT 1 (4) 2 (14)
Progression after ASCTa 7 (26) 7 (46)
BL/BLL: Burkitt, Burkitt-like lymphoma; LyLy: lymphoblastic lymphoma.
aMedian follow-up 61 months.
Table 2 Toxic side effects by treatment course
Toxicity CTC-grade Percentage of patients with toxicity
Induction-I (n¼ 42) Induction-II (n¼ 41) ASCT (n¼36)
2 3 2 3 4 2 3 4
Oral 12 2 32 12 27 17 17 17
Cutaneous/allergy 7 F 5 F F 8 F F
Liver 5 5 F 2 F 8 F F
Hemorrhage 2 F F F F 3 F F
Diarrhea F 2 7 F F 8 3 F
Renal F 2 F F F F F F
Cardial 2 F 2 F F 6 F F
Neurotoxicity 5 2 5 F F 8 3 F
Bone pain 2 F F F F F F F
Other 29 2 20 5 F 22 6 F
Infections (WHO grade) 31 10 46 10 F 25 25 F
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not available. In addition, it has been argued that as BLL
represents a high-grade aggressive lymphoma much closer to BL
than DLBCL, inclusion of BLL as a variant of BL is biologically
and clinically more appropriate than absorbing the category of
BLL into DLBCL.29 Thus, until now, tumor morphology and
immuno-phenotype have been used as main diagnostic criteria
for patient entry in prospective clinical studies on BL and we are
not aware of clinical studies prospectively based on inclusion of
only MYC/8q24 positive cases. Although considered to be the
pathogno-monic hallmark of BL, MYC/8q24 breakpoints are not
exclusively found in BL but can also be detected in some
morphologically undisputed cases of DLBCL.30 Further-more,
not all BL have a breakpoint that can be detected by currently
used FISH assay.26 Moreover, whether the presence of a MYC/
8q24 breakpoint in itself confers a specific prognostic value for
outcome of treatment still remains to be investigated. In the
present series of 27 BL/BLL, according to the REAL classification,
no apparent difference in clinical presentation or outcome was
detected between the different morphological subgroups and
between the breakpoint positive, negative, and not tested cases;
however, numbers of patients obviously were too small to draw
any firm conclusions.
Although prognostic factors have been recognized in BL, no
formally validated risk classification according to prognostic
factors exists for BL, making comparison of treatment outcome
of different studies difficult. For instance, according to the IPI7
only 37% of our BL/BLL patients had high-risk disease, but this
index has been primarily designed for and validated in patients
with aggressive lymphoma treated with CHOP-like chemother-
apy excluding BL/BLL and LyLy. In childhood BL, the St Jude
staging system as developed by Murphy31 has been widely used
for risk classification. According to this classification, 17 (62%)
of our BL/BLL patients had advanced stage disease. For reasons
of comparison with other recently published treatment regimens
of adult patients with BL/BLL, we have also reclassified our
patients according to the UKLG risk score.23 This score, which is
equivalent to that used by investigators at NCI in trials 77-04
and 89-C-41 for both childhood and adult BL9 and in Boston for
adult BL/BLL,24 showed that 89% of our patients could be
classified as high-risk BL/BLL.
Treatment with DLBCL-like regimens may be curative in
patients with low-risk BL, presenting with nonextensive, nodal
disease.32–36 However, this treatment approach is not sufficient
in patients with high-risk disease, that is, more extensive and
extranodal disease, especially in the presence of extensive bone
marrow and/or CNS involvement.9 Remarkable improvements
in the outcome of patients with high-risk disease, even in those
with overt leukemic BL or CNS involvement, have been
attributed to the addition of high-dose intravenous MTX
and Ara-C to the treatment in children3,4,6 as well as in
adults.8–12,23,24,37 At high dosages both drugs penetrate well the
CNS, which may be one of the reasons of their apparent
efficacy. The HOVON-27BL does not contain high-dose MTX
and only low-dose Ara-C in the BEAM regimen. Although CNS
prophylaxis was mandatory in patients with BL and LyLy at the
time this study started, the optimal prophylaxis including the
type and amount of (intrathecal) drugs was still under debate
and the toxicity of high-dose intravenous MTX and or Ara-C,
especially in elderly patients, well documented.8–12 Apart from
intrathecal MTX (at that time our standard prophylactic
intrathecal regimen for lymphoma), our protocol incorporated
intravenous high-dose etoposide in the induction regimen as
well as high-dose carmustine in the BEAM regimen, drugs both
well able to penetrate the blood–brain barrier. We omitted high-
dose intravenous MTX or Ara-C in our regimen to avoid possible
excessive toxicity. Whether, in retrospect, this was sufficient for
CNS prophylaxis in BL patients without extensive CNS or bone
marrow involvement is debatable, given one BL with meningeal
disease during induction treatment.
In contrast to our results in BL/BLL, patients with LyLy fared
less well. The discrepancy between LyLy and BL treated with the
same regimen is remarkable, suggesting that treatment outcome
is more dependent on the type of tumor cell than on clinical
presentation. BL, like most aggressive lymphomas originating
from follicle center cells, seems to respond well to this
lymphoma-type regimen. In contrast, LyLy, derived from
precursor B- or T-cells, ultimately responded poorly to this
short treatment. Although a comparable complete remission rate
of 73% was reached, a substantial number of patients with LyLy
relapsed and EFS was only 40% at 5 years. The number of LyLy
patients treated with this regimen was too small to draw firm
conclusions on any relation with either original extent of disease
or the pattern of relapse. As has been the experience in the
treatment of children with LyLy,38 this type of lymphoid
malignancy probably needs treatment of longer duration as in
acute lymphoblastic leukemia.39 We and others have reported
excellent results with 2–3 years maintenance therapy together
with consolidation courses after induction chemotherapy in
adult precursor B- and T-ALL.16,40 Whether additional benefit
can be obtained by ASCT in patients in first CR remains
questionable. A randomized multicenter study in adult patients
with LyLy, comparing ASCT with conventional-dose chemother-
apy in patients responding to induction chemotherapy failed to
show a survival benefit for the ASCT arm, although this study
had to be closed before the projected number of patients was
reached because of accrual problems.41
Figure 1 Overall survival and event free survival of BL/BLL and
LyLy patients.
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Table 4 Overview of adult Burkitt, Burkitt-like/small non-cleaved-cell lymphoma treatment
Reference Histology Patients
number
Age
median
(range)
Ann Arbor
stage III–IV
BM+ CNS+ Regimen MTX
(g/m2)
Etoposide
(mg/m2)
Ara-C
(mg/m2)
Last
Treatment
months
after
diagnosis
Complete
response
Median
follow-up
months
(range)
Actuarial
overall
survival
SNCCL Per cycle Per cycle Per cycle
Bernstein 1986 SNCCL 18 25 (15–75) 44% 11% 0% M-CHOP/XRT 3 none none 4–6 78% 14 67% 2y
Lopez 1990 SNCCL 45 32 (17–72) 59% 16% 2% MDA 81-01/84-30 1 100 3 200 8 6.4 80% nk 52% 5y
McMaster 1991 SNCCL 20 45 (21–69) 90% 30% 15% M-BCHEOP 0.2 100–400 3 none 2 85% 29 60% 5y
Longo 1994 SNCCL 33 36 (19–80) 49% 9% 0% ProMACE+ 3–0.1 100 300 8 82% 120 60% 10y
Magrath 1996 SNCCL 39 24 (18–56) 77% nka nk NCI 77-04 2.8 none none 15 nk (72–200) 56% 5y
BL
Magrath 1996 BL 20 25 (18–59) 70% nkb nkb NCI 89-c-41 6.7 60 5 2000 4 3.8 100% 32 100% 3y
Mead 2002 BL 52 35 (15–60) 61% 40% 13% UKLG LY06 6.7 60 5 2000 4 2.3 77% 35 73% 2y
Lacasce 2004 BL 14 47 (18–65) nk 36% 0% Modified Magrath 3 60 5 2000 4 nk 86% 29 71% 2y
Di Nicola 2004d BL 22 36 (18–76) 50% 14% 5% INT, Milan e 250 2 1750 4 3 77% 29 77% 12y
Current Study BL 27 36 (15–64) 44% 7% 0% HOVON-27BL none 250 8 none 2.3 81% 61 81% 5y
BL & Leukemic
Soussain 1995 BL 65 26 (17–65) 70% 33%f 18% LMB 84,86,89 3–8 200 4 3000 3 2.5 89% 57 74% 3y
Lee 2001 BL 54 44 (18–71) nk 61% 4% NHLB86 1.5 80 2 150 5.1 80% 61 52% 5y
BL Leukemic
Hoelzer 1996 BL 24 36 (18–65) Leukemic 100% 12% NHL-B83 0.5 165 300 4 5.3 63% nk 49% 8y
Hoelzer 1996 BL 35 33 (18–58) Leukemic 100% 12% NHL-B86 1.5 100 2c 150 4 74% nk 51% 4y
Thomas 1999 BL 26 58 (17–79) Leukemic 100% 42% Hyper-CVAD 1 none 3000 4 5.3 81% nk 49% 3y
BL: Burkitt and Burkitt-like lymphoma; SNCCL: small non-cleaved-cell lymphoma.
ank: not known (not reported).
bnot known: 3 patients with either BM or CNS involvement.
cVM26.
dPatients not in CR or relapse were treated with rituximab with high-dose therapy and autologous stem cell transplantation.
e150 mg/kg d 7 and 250 mg/kg d 21.
fnumber of patients with 450% blasts in bone marrow.
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Given the small numbers of adult patients with BL/BLL, the
different mix of risk factors, histologies, staging classification
and follow-up presented in the literature, it is difficult to directly
compare the results of the HOVON-27BL regimen with those of
other treatment schemes (Table 4). The 81% OS and 73% EFS, at
5 years are excellent, without the use of high-dose MTX and
high-dose Ara-C. Evidently, only phase III trials can answer the
question how this scheme compares to the usually applied
regimens for adult patients with BL/BLL. Given the rarity of the
disease in adults, this will require a world wide intergroup
organization.
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